<DOC>
	<DOCNO>NCT00202020</DOCNO>
	<brief_summary>The study design subject relevant SFDA regulation clinical trial . This indication approve Japan 2003 . From end May 2004 end Dec. 2004 , 720 patient previous cerebral infarction ( see inclusion criterion ) enrol study receive one two treatment regimen , Cilostazol Aspirin , ratio patient number group 1:1 . For patient , chance enter either two group . The treatment continue till end 2005 . During treatment period , patient observe concern certain event , mainly reoccurrence stroke . If patient experience reoccurrence stroke , event doctor think appropriate continue study medication , patient would stop treatment . Patients also require take MRI head scan entering study completion treatment .</brief_summary>
	<brief_title>Efficacy Safety Study Cilostazol Prevent Reoccurrence Stroke</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Patients cerebral infarction within 6 month 1 month entry 2 . Within day onset cerebral infarction onset , CT MRI show evidence infarction could responsible stroke onset 3 . A modified rank scale le 4 4 . Aged 18~75 5 . Consent patient legal guardian 1 . History intracranial hemorrhage 2 . Stroke secondary cardiogenic embolism 3 . Serious damage motorial function , dementia 4 . Serious complication co morbidity ( uncontrolled accelerate type hypertension , BP &gt; 180/120mmHg , diabetic acidosis , heart failure , renal failure , hepatocirrhosis , malignant tumor ) 5 . Contraindication Cilostazol Aspirin 6 . Patients need co medication antiplatelet agent , anticoagulant fibrinolytic drug 7 . Active peptic ulcer 8 . Pregnancy breast feed 9 . Judged inappropriate enter study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Cerebral infarction</keyword>
	<keyword>Prevention</keyword>
	<keyword>Cilostazol</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Stroke</keyword>
	<keyword>Clinical trial</keyword>
</DOC>